Lipid Reagents

(3β)-24-Bromo-3-[(tert-butyl)dimethylsilyloxy]-chol-5-ene.

(3S)-(+)-3-(1-METHYLINDOL-3-YL)-3-PHENYLPROPIONIC ACID-

(4-ACETYLAMINO-BENZENESULFONYLAMINO)-CYCLOHEXA-1 4-DIENYL-ACETIC ACID-

(4-Bromo-1,2-phenylene)dimethanol.

(4-Bromo-1,2-phenylene)dimethanol.

(4R,5R)-2,2-Dimethyl-α,α,α',α'-tetra(1-naphthyl)-1,3-dioxolane-4,5-dimethanol.

(6-Methyl-4-oxothieno[2,3-d]pyrimidin-3(4H)-yl)acetic acid.

(6R,7R)-7-Phenylacetamido-3-[(Z)-2-(4-methylthiazol-5-yl)ethenyl]-3-cephem-4-carboxylic Acid Diphenyl Methyl Ester is a Cephalosporin intermediate.

(±)9-HODE cholesteryl ester was originally extracted from atherosclerotic lesions and shown to be produced by Cu|2+|-catalyzed oxidation of LDL. Studies later determined that 15-LO from rabbit reticulocytes and human monocytes were able to

(±)9-HODE cholesteryl ester was originally extracted from atherosclerotic lesions and shown to be produced by Cu|2+|-catalyzed oxidation of LDL. Studies later determined that 15-LO from rabbit reticulocytes and human monocytes were able to

(±)-Vasicine is the racemate of Vasicine. Vasicine (Peganine) significantly inhibits H + -K + -ATPase activity in vitro with an IC 50 of 73.47 μg/mL. Anti-ulcer activity. Vasicine shows significant anti-secretory, antioxidant

(±)-Vasicine is the racemate of Vasicine. Vasicine (Peganine) significantly inhibits H + -K + -ATPase activity in vitro with an IC 50 of 73.47 μg/mL. Anti-ulcer activity. Vasicine shows significant anti-secretory, antioxidant